New pill hopes to tame relapsed blood cancers in early trial

NCT ID NCT05347225

First seen May 12, 2026 · Last updated May 21, 2026 · Updated 5 times

Summary

This early-phase study tests an oral drug called MK-1026 in 12 Chinese adults with blood cancers that have returned or not responded to prior treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. This is not a cure; the drug aims to control the disease, and participants may need ongoing treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Guangdong Provincial People's Hospital-hematology department ( Site 1002)

    Guangzhou, Guangdong, 510080, China

  • Henan Cancer Hospital-hematology department ( Site 1003)

    Zhengzhou, Henan, 450008, China

  • Hunan Cancer Hospital ( Site 1004)

    Changsha, Hunan, 410013, China

  • Institute of hematology&blood disease hospital-Hematology ( Site 1001)

    Tianjin, Tianjin Municipality, 301636, China

  • SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007)

    Guangzhou, Guangdong, 511400, China

Conditions

Explore the condition pages connected to this study.